Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international study.

内容摘要

To describe epidermal growth factor receptor (EGFR) mutation (EGFRm) testing practices and treatment patterns in EGFRm-positive patients with advanced/metastatic non-small cell lung cancer (NSCLC) and evaluate clinical outcomes. Data were drawn from a cross-sectional, retrospective chart review of adult patients with advanced/metastatic NSCLC in Argentina, Belgium, Brazil, India, the Netherlands, Russia, Singapore, Switzerland, and Türkiye between June-September 2021. Eligible patients had an initial advanced/metastatic stage NSCLC diagnosis, and positive first EGFRm test between April 2017-March 2018. Data were reported from NSCLC diagnosis to end of follow-up (June-2020) or death. Index was the receipt date of EGFRm result. Analyses were descriptive. Overall, 208 physicians reported data on 947 patients. Mean (standard deviation) age at diagnosis was 60.3 (10.9) years and 79.4% had an ECOG 0-1. EGFRm was identified by single-gene (64.0%) and multi-gene (36.0%) panel testing. Median (interquartile range) turnaround time was 14 (10-22) days. Prior to and following index, 26.9% and 68.6% of patients, respectively, were administered EGFR-tyrosine kinase inhibitors (EGFR-TKI) as first-line (1 L) treatment. Disease progression occurred in 60.4% and 70.1% pre-index and post-index, respectively. Among those receiving 1 L EGFR-TKI, partial response was reported in 56.5% of patients pre-index and in 65.0% post-index. The median overall survival on post-index 1 L EGFR-TKI was not reached. EGFRm status was mostly determined by single-gene testing, and around one-quarter of patients were prescribed pre-index 1 L EGFR-TKI. Further research into outcomes for EGFRm-positive patients not receiving 1 L EGFR-TKI, and pre-index vs post-index treatment would be valuable.